ArticleMarine drugs2016
Production of the Marine Carotenoid Astaxanthin by Metabolically Engineered Corynebacterium glutamicum.
Article in Marine drugs, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 119 citations in OpenAlex.
- Novel utilization of the seaweed-based deoxy sugars rhamnose and fucose by engineered Corynebacterium glutamicum.Microbial cell factories · 2026Article
- Pathway reconstruction of Corynebacterium glutamicum for C30 carotenoid 4,4'-diaponeurosporene production.Journal of biological engineering · 2026Article
- Heterologous Production of 2,2'-Dihydroxy Derivatives of Astaxanthin and Adonirubin inAntioxidants (Basel, Switzerland) · 2026Article
- Design and validation of an inducible and curable EvolvR system for directed evolution inFrontiers in bioengineering and biotechnology · 2026Article
- Strategic selection of microbial cell factories for sustainable and application-specific terpenoid production.Frontiers in bioengineering and biotechnology · 2026Review
- Installing a Ketocarotenoid Branch inMarine drugs · 2025Article
- Supercritical carbon dioxide extraction of astaxanthin from Corynebacterium glutamicum.Bioresources and bioprocessing · 2025Article
- EngineeredLife (Basel, Switzerland) · 2025Article
- Astaxanthin: a nature's versatile compound utilized for diverse applications and its therapeutic effects.3 Biotech · 2025Review
- Last Decade Insights in Exploiting Marine Microorganisms as Sources of New Bioactive Natural Products.Marine drugs · 2025Review
- EngineeringBiodesign research · 2025Review
- Response surface-based media optimization for astaxanthin production inFrontiers in bioengineering and biotechnology · 2025Article
- Expanding the CRISPR Toolbox for Engineering Lycopene Biosynthesis inMicroorganisms · 2024Article
- Enhancing astaxanthin biosynthesis and pathway expansion towards glycosylated C40 carotenoids by Corynebacterium glutamicum.Scientific reports · 2024Article
- Extraction and Purification of Highly Active Astaxanthin fromMarine drugs · 2023Article
- Review
- Metabolic Engineering of Model Microorganisms for the Production of Xanthophyll.Microorganisms · 2023Review
- High-efficiency production of the antimicrobial peptide pediocin PA-1 in metabolically engineered Corynebacterium glutamicum using a microaerobic process at acidic pH and elevated levels of bivalent calcium ions.Microbial cell factories · 2023Article
- From Aquaculture to Aquaculture: Production of the Fish Feed Additive Astaxanthin byMolecules (Basel, Switzerland) · 2023Article
- Rational Engineering of Non-Ubiquinone ContainingMetabolites · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Astaxanthin, a red C40 carotenoid, is one of the most abundant marine carotenoids. It is currently used as a food and feed additive in a hundred-ton scale and is furthermore an attractive component for pharmaceutical and cosmetic applications with antioxidant activities. Corynebacterium glutamicum, which naturally synthesizes the yellow C50 carotenoid decaprenoxanthin, is an industrially relevant microorganism used in the million-ton amino acid production. In this work, engineering of a genome-reduced C. glutamicum with optimized precursor supply for astaxanthin production is described. This involved expression of heterologous genes encoding for lycopene cyclase CrtY, β-carotene ketolase CrtW, and hydroxylase CrtZ. For balanced expression of crtW and crtZ their translation initiation rates were varied in a systematic approach using different ribosome binding sites, spacing, and translational start codons. Furthermore, β-carotene ketolases and hydroxylases from different marine bacteria were tested with regard to efficient astaxanthin production in C. glutamicum. In shaking flasks, the C. glutamicum strains developed here overproduced astaxanthin with volumetric productivities up to 0.4 mg·L(-1)·h(-1) which are competitive with current algae-based production. Since C. glutamicum can grow to high cell densities of up to 100 g cell dry weight (CDW)·L(-1), the recombinant strains developed here are a starting point for astaxanthin production by C. glutamicum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.